# Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting Canonical URL: https://biopharmsignal.com/news/CLLS/cellectis-presents-epigenetic-editing-platform-to-turn-genes-off-without-altering-dna-at-the-asgct-annual-meeting Ticker: CLLS Company: Cellectis Source: Cellectis Published: 2026-04-27 14:14 EST Original Source URL: https://www.cellectis.com ## Summary

New York, NY – April 27, 2026 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company u ## Article Body New York, NY - April 27, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today presents new research on a TALE-based epigenetic editing approach, that does not cut or permanently modify the DNA sequence, making it a potentially safer alternative for genome editing, at the American Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 11-15, in Boston (MA). The data will be presented in a poster: Title: TALE-based epigenetic modulators show sustained knock-down of target genes in T-cells and HEPG2 via a high-throughput multiplex screening platform Transcription activator-like effector-based epigenetic modulators (TALEM) are engineered fusion proteins consisting of a TALE DNA-binding domain with functional domains that mediate epigenetic modifications. These proteins can be precisely guided to a target location in the genome to switch genes on or off through a process known as epigenetic editing. Unlike traditional gene editing tools, this approach does not induce DNA breaks and DNA sequence modifications, making it a potentially safer alternative for genome editing. In this work, Cellectis developed a high-throughput screening system capable of rapidly assembling and testing hundreds of these TALEM, identifying which combinations are most effective at regulating a given gene. The results: This strategy was used for two distinct genes: one highly expressed in hepatocytes (active in liver cells) and another implicated in T-cell dysfunction and exhaustion, a key challenge in cancer immunotherapy. In both cases, the approach achieved >90% reduction in gene activity, which remained stable throughout the study. "We are excited to present these results at ASGCT, which demonstrate Cellectis' ability to apply its gene editing platform into the emerging field of epigenetic editing" said Louisa Mayer, Ph.D., Scientist II and Supervisor - Innovation & Gene Editing at Cellectis. "This work shows our ability to design and identify highly potent epigenetic editors across different cell types, thereby enriching our gene‑editing toolbox." The abstract is published on the ASGCT website. The poster will be available on Cellectis' website on the presentation day, Wednesday May 13, 2026 at 5 pm ET. ## Recent Company News - 2026-06-25 20:30 EST — [Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026](https://biopharmsignal.com/news/CLLS/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026-28c487bb) — Source: Cellectis - 2026-06-11 06:40 EST — [Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress](https://biopharmsignal.com/news/CLLS/cellectis-presents-final-phase-1-results-of-lasme-cel-and-preliminary-results-on-ea9f9ebc) — Source: Cellectis - 2026-06-09 20:30 EST — [Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL](https://biopharmsignal.com/news/CLLS/cellectis-receives-fda-rmat-designation-for-lasme-cel-the-first-allogeneic-car-t-629c5c17) — Source: Cellectis - 2026-05-20 20:30 EST — [Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026](https://biopharmsignal.com/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-june-25-2026) — Source: Cellectis - 2026-05-12 13:30 EST — [Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress](https://biopharmsignal.com/news/CLLS/cellectis-to-present-clinical-data-on-lasme-cel-and-eti-cel-at-eha-2026-annual-congress) — Source: Cellectis ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)